treatment group:Anlotinib

2 trials

Sponsors

Oncology Department, Guangdong Provincial Hospital of Chinese Medicine

Conditions

epithelial ovarian cancer

Phase 4

Clinical study of Anlotinib as Third-Line or Further Treatment on Advanced Epithelial Ovarian Cancer

RecruitingITMCTR1900002442

Oncology Department, Guangdong Provincial Hospital of Chinese Medicineepithelial ovarian cancer

Start: 2019-07-03Updated: 2023-02-20

Clinical study of Anlotinib as Third-Line or Further Treatment on Advanced Epithelial Ovarian Cancer

RecruitingChiCTR1900024312

Oncology Department, Guangdong Provincial Hospital of Chinese Medicineepithelial ovarian cancer

Start: 2019-07-03Updated: 2019-07-15